<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>TanyaDok</title>
    <link rel="stylesheet" href="resources/css/news-page.css" />
  </head>
  <body>
    <header>
      <div class="container">
        <h1>TanyaDok Articles</h1>
        <nav>
          <ul>
            <li><a href="news-page2.html">Previous Page</a></li>
            <li><a href="dashboard.html">Home</a></li>
            <li><a href="news-page4.html">Next Page</a></li>
          </ul>
        </nav>
      </div>
    </header>

    <main>
      <div class="container">
        <article>
          <header style="border-radius: 10px">
            <h2>
              Keytruda (Pembrolizumab): A Breakthrough in Cancer Immunotherapy
            </h2>
            <p class="meta">December 15, 2024</p>
          </header>
          <img
            src="resources/images/page3-photo.png"
            alt="Article Image"
            class="article-image"
          />
          <p>
            Cancer has long been one of the most formidable health challenges
            worldwide, claiming millions of lives each year. Traditional cancer
            treatments, such as chemotherapy, radiation, and surgery, have saved
            countless lives but are not without their limitations. In recent
            years, the rise of immunotherapy has ushered in a new era of cancer
            treatment, with **Keytruda (pembrolizumab)** standing out as one of
            the most promising breakthroughs in cancer therapy.
          </p>
          <p>
            Keytruda is a revolutionary drug that harnesses the power of the
            body's immune system to fight cancer. Approved by the U.S. Food and
            Drug Administration (FDA) in 2014, pembrolizumab has transformed the
            landscape of oncology treatment, offering hope to patients with
            cancers that were once difficult to treat. But what exactly is
            Keytruda, how does it work, and what cancers can it treat? Let’s
            dive deeper into this life-changing medication.
          </p>
          <h3>What is Keytruda (Pembrolizumab)?</h3>
          <p>
            Keytruda (generic name: pembrolizumab) is a type of monoclonal
            antibody used as an immune checkpoint inhibitor. Immune checkpoint
            inhibitors are a class of drugs that block the interactions between
            certain proteins that stop the immune system from attacking cancer
            cells. Pembrolizumab specifically targets and blocks the PD-1
            receptor, a protein found on immune cells, which is often hijacked
            by cancer cells to evade detection by the immune system.
          </p>
          <p>
            By inhibiting PD-1, pembrolizumab allows the immune system to
            recognize and attack cancer cells more effectively. This makes it a
            form of immunotherapy, a treatment that uses the body’s own immune
            system to fight cancer, in contrast to traditional treatments that
            directly target and kill cancer cells.
          </p>
          <h3>How Does Keytruda Work?</h3>
          <p>
            In the body, immune cells called T-cells are responsible for
            identifying and attacking abnormal cells, including cancer cells.
            However, many cancer cells have the ability to "hide" from the
            immune system by binding to the PD-1 receptor on T-cells. This
            interaction suppresses the immune system’s ability to fight off the
            cancer cells, allowing the cancer to grow and spread.
          </p>
          <p>
            Pembrolizumab works by blocking the PD-1 receptor on T-cells,
            preventing cancer cells from turning off the immune response. This
            enables the immune system to detect and destroy cancer cells more
            efficiently. Essentially, Keytruda acts as a “reawakening” for the
            immune system, allowing it to better fight cancer.
          </p>
          <h3>Approved Uses of Keytruda</h3>
          <p>
            Keytruda has demonstrated significant success in treating a wide
            range of cancers, including some of the most difficult-to-treat
            types. It has been approved for use in several indications, either
            as a standalone treatment or in combination with other therapies.
            Some of the key cancers that Keytruda has been approved to treat
            include:
          </p>
          <ul>
            <li>
              <strong>Non-Small Cell Lung Cancer (NSCLC)</strong> One of the
              most significant approvals for Keytruda was in the treatment of
              non-small cell lung cancer (NSCLC), the most common form of lung
              cancer. Pembrolizumab has been shown to improve overall survival
              rates in patients with advanced NSCLC, especially when other
              treatment options have failed.
            </li>
            <li>
              <strong>Melanoma</strong> Keytruda has been a game-changer for
              patients with advanced melanoma, a type of skin cancer. It has
              improved survival rates for patients with metastatic melanoma,
              where the cancer has spread to other parts of the body.
            </li>
            <li>
              <strong>Head and Neck Cancer</strong> Pembrolizumab is also
              approved for the treatment of head and neck squamous cell
              carcinoma (HNSCC), a cancer that affects the mucosal surfaces of
              the head and neck. For patients with advanced HNSCC, Keytruda has
              shown improved survival rates.
            </li>
            <li>
              <strong>Hodgkin Lymphoma</strong> For patients with Hodgkin
              lymphoma that relapses or is resistant to other treatments,
              Keytruda has been approved as a treatment option, offering new
              hope to patients who previously had few alternatives.
            </li>
            <li>
              <strong>Urothelial Carcinoma (Bladder Cancer)</strong> Keytruda is
              approved for use in patients with bladder cancer, specifically
              urothelial carcinoma, who have disease progression during or after
              chemotherapy. Pembrolizumab has shown promising results in
              improving survival rates in these patients.
            </li>
            <li>
              <strong>Cervical Cancer</strong> Pembrolizumab has been approved
              to treat cervical cancer in certain patients, particularly those
              with advanced or metastatic disease that expresses the PD-L1
              protein. It offers another treatment option for women with
              recurrent cervical cancer.
            </li>
            <li>
              <strong>Other Cancers</strong> In addition to these, Keytruda is
              also being explored for use in treating several other cancers,
              including esophageal cancer, gastric cancer, liver cancer, and
              mesothelioma. Ongoing clinical trials are examining its potential
              in combination with other therapies for various cancers.
            </li>
          </ul>
          <h3>The Future of Keytruda and Cancer Treatment</h3>
          <p>
            Keytruda represents a major step forward in cancer treatment,
            offering patients new hope when traditional therapies have failed.
            Its ability to activate the immune system and help the body’s own
            defenses recognize and destroy cancer cells has led to significant
            advancements in treating cancers that were once difficult to treat.
          </p>
          <p>
            As research continues, the potential applications for Keytruda are
            expanding. Clinical trials are exploring its efficacy in various
            combinations with other drugs, including other immune checkpoint
            inhibitors, chemotherapy, and targeted therapies. The future of
            Keytruda is bright, as it holds the promise of offering personalized
            and effective cancer treatments to more patients worldwide.
          </p>
        </article>
      </div>
    </main>

    <footer>
      <div class="container">
        <p>&copy; 2024 TanyaDok. All rights reserved.</p>
      </div>
    </footer>
  </body>
</html>
